Depo-SubQ Provera 104 is a birth control injection that contains 104 mg of the hormone progestin (medroxyprogesterone acetate) and provides an effective protection from pregnancy for 3 months.
Indications for use
- Contraception, especially in women of late reproductive age;
- Inoperable, recurrent and metastatic carcinoma of endometrium and kidney (additional palliative therapy), hormone-dependent forms of recurrent breast cancer in postmenopausal women.
Mechanism of action
Medroxyprogesterone acetate (MPA) is a progesterone derivative that does not possess estrogenic activity and is associated with progestins. Androgenic activity of the compound is minimized. MPA in therapeutic doses reduces the production of gonadotropins of the pituitary gland, preventing the maturation of follicles and causing an anovulatory state in women of reproductive age. This effect leads to a decrease in the severity of symptoms of a vasomotor character in women in the menopausal period. MPA also increases the viscosity of the cervical mucus accumulating in the cervical canal, as a result of which the penetration of spermatozoa becomes practically impossible. In some cases, the anabolic effect and anti-inflammatory effect of the drug is noted. In large doses, it has a glucocorticosteroid activity.
Mode of application and dosage
You should get an injection of 104 mg of Depo-Subq Provera 104 once every 3 months. The first administration should be prescribed only on the 5th day of a normal period. It is necessary to use an additional method of contraception within 2 weeks after the first injection.
Do not use Depo-SubQ Provera 104 if you have any of the following conditions:
- hypersensitivity to medroxyprogesterone acetate;
- thromboembolic syndrome or stroke in an anamnesis;
- liver disease;
- vaginal bleeding of an unspecified etiology;
- breastfeeding period
In some cases, the birth control injection may cause the following side effects:
- allergic reactions: anaphylaxis and anaphylactoid reactions, urticaria;
- blood coagulation system: thromboembolism, thrombophlebitis;
- central nervous system: increased nervous excitability, insomnia, drowsiness, fatigue, depression, dizziness, headache;
- dermatological reactions: itching, rashes, acne, hirsutism and alopecia;
- reproductive system: dysfunctional uterine bleeding, spotting from the genital tract, amenorrhea, decreased libido or anorgasmia, vaginitis, whitecaps, tidal pains, lower abdominal pain, breast tenderness, galactorrhea;
- digestive system: pain or discomfort in the abdomen, nausea, flatulence;
- musculoskeletal system: spasms of the calf muscles, pain in the back and joints;
- other: asthenia, hyperthermia, change in body weight and moonlike face
Aminoglutethimide may significantly reduce the bioavailability of medroxyprogesterone acetate.
Depo-SubQ Provera 104 and pregnancy
Pregnancy is a contraindication to the use of Depo-SubQ Provera 104 because in some cases a link between the intake of progestogens in the first trimester of pregnancy and fetal development anomalies is revealed. With an unplanned pregnancy that occurred 1-2 months after an injection of MPA, the risk of hypotrophy in newborns increases, which increases the risk of intrapartum and neonatal mortality. Such complications are infrequent since conception against the background of this drug is rare. If pregnancy has occurred immediately after the introduction of MPA, a woman should be warned about the possible risks to the fetus. The substance penetrates into breast milk. Data on how this may affect a baby is not available but it is not recommended to prescribe this birth control method during the first 6 weeks of the postpartum period.